Sec Form 4 Filing - Shapiro Lucy @ Anacor Pharmaceuticals, Inc. - 2014-12-10

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Shapiro Lucy 2. Issuer Name and Ticker or Trading Symbol Anacor Pharmaceuticals, Inc. [ ANAC] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE 3. Date of Earliest Transaction (MM/DD/YY) 12/10/2014 (Street) PALO ALTO, CA94303 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 12/10/2014 M 3,000 A $ 7.25 39,248 D Common Stock 12/10/2014 S 3,000 D $ 35.7864 ( 1 ) 36,248 D Common Stock 12/10/2014 M 834 A $ 0.6 37,082 D Common Stock 12/10/2014 S 834 D $ 35.7864 ( 1 ) 36,248 D Common Stock 12/10/2014 M 15,000 A $ 5.11 51,248 D Common Stock 12/10/2014 S 15,000 D $ 35.7864 ( 1 ) 36,248 D Common Stock 12/10/2014 M 12,500 A $ 5.2 48,748 D Common Stock 12/10/2014 S 12,500 D $ 35.7864 ( 1 ) 36,248 D Common Stock 12/10/2014 M 7,500 A $ 14.22 43,748 D Common Stock 12/10/2014 S 7,500 D $ 35.7864 ( 1 ) 36,248 D Common Stock 12/10/2014 M 15,000 A $ 6.74 51,248 D Common Stock 12/10/2014 S 15,000 D $ 35.7864 ( 1 ) 36,248 D Common Stock 12/10/2014 M 30,000 A $ 6.92 66,248 D Common Stock 12/10/2014 S 30,000 D $ 35.7864 ( 1 ) 36,248 D Common Stock 12/10/2014 M 1,500 A $ 7.55 37,748 D Common Stock 12/10/2014 S 1,500 D $ 35.7864 ( 1 ) 36,248 D Common Stock 12/10/2014 M 687 A $ 17.14 36,935 D Common Stock 12/10/2014 S 687 D $ 35.7864 ( 1 ) 36,248 D Common Stock 12/10/2014 M 3,000 A $ 5.54 39,248 D Common Stock 12/10/2014 S 3,000 D $ 35.7864 ( 1 ) 36,248 D Common Stock 12/11/2014 S 30,801 D $ 34.9074 ( 2 ) 5,447 D Common Stock 12/11/2014 S 120,032 D $ 34.923 72,384 I MCADAMS-SHAPIRO FAMILY TRUST DTD MAY 24, 1999 Common Stock 12/12/2014 S 44,384 D $ 34.4465 28,000 I MCADAMS-SHAPIRO FAMILY TRUST DTD MAY 24, 1999 Common Stock 12/12/2014 S 5,447 D $ 34.48 0 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 7.25 12/10/2014 M 3,000 ( 3 ) 01/25/2018 Commmon Stock 3,000 $ 7.25 0 D Stock Option (right to buy) $ 0.6 12/10/2014 M 834 ( 3 ) 10/26/2015 Common Stock 834 $ 0.6 0 D Stock Option (right to buy) $ 5.11 12/10/2014 M 15,000 ( 3 ) 06/06/2023 Common Stock 15,000 $ 5.11 0 D Stock Option (right to buy) $ 5.2 12/10/2014 M 12,500 ( 3 ) 05/30/2022 Common Stock 12,500 $ 5.2 0 D Stock Option (right to buy) $ 14.22 12/10/2014 M 7,500 ( 4 ) 05/29/2024 Common Stock 7,500 $ 14.22 7,500 D Stock Option (right to buy) $ 6.74 12/10/2014 M 15,000 ( 3 ) 05/25/2021 Common Stock 15,000 $ 6.74 0 D Stock Option (right to buy) $ 6.92 12/10/2014 M 30,000 ( 3 ) 03/31/2021 Common Stock 30,000 $ 6.92 0 D Stock Option (right to buy) $ 7.55 12/10/2014 M 1,500 ( 3 ) 08/20/2020 Common Stock 1,500 $ 7.55 0 D Stock Option (right to buy) $ 17.14 12/10/2014 M 687 ( 5 ) 02/07/2024 Common Stock 687 $ 17.14 813 D Stock Option (right to buy) $ 5.54 12/10/2014 M 3,000 ( 3 ) 01/12/2022 Common Stock 3,000 $ 5.54 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Shapiro Lucy C/O ANACOR PHARMACEUTICALS, INC. 1020 EAST MEADOW CIRCLE PALO ALTO, CA94303 X Signatures /s/ Lucy O. Day, as attorney-in-fact 12/12/2014 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $35.51 to $36.44, inclusive. ( 2 )The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $34.68 to $35.66, inclusive. ( 3 )This option is fully vested and exercisable. ( 4 )1/12th of the shares subject to the option shall vest and become exercisable in a series of twelve equal monthly installments measured from May 29, 2014. ( 5 )1/24th of the shares subject to the option shall vest and become exercisable on a monthly basis over the twenty-four months following the vesting commencement date of January 1, 2014.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.